Nexcella announced that updated NXC-201 clinical data has been selected to be presented at the upcoming 49th annual meeting of the European Society for Blood and Marrow Transplantation to be held in Paris, France, 23-26 April 2023. Posters to be presented: Title: "Point-of-care CART manufacture and delivery for the treatment of multiple myeloma and AL amyloidosis: the experience of Hadassah Medical Center" / Nexcella, Inc. previously announced that NXC-201 produced a 90% overall response rate and 59% complete response/stringent complete response at the therapeutic dose from the first 42 patients in an ongoing phase 1b/2a relapsed/refractory multiple myeloma ongoing clinical trial as of the October 23, 2022 data cutoff. NXC-201 also produced 100% hematologic complete response rate and 100% organ response rate in 5 relapsed/refractory AL Amyloidosis patients as of the October 23, 2022 data cutoff. Low-grade CRS duration of median 2 days with median onset of 1-day post-dosing at therapeutic dose in relapsed/refractory multiple myeloma points to NXC-201 potentially becoming the first and only out-patient CAR-T for Multiple Myeloma, AL Amyloidosis and other BCMA-positive malignancies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IMMX:
- Nexcella, an Immix Biopharma subsidiary, announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting
- Immix Biopharma’s Nexcella announces 2023 Haematologica editorial on NXC-201
- Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells
- Immix Biopharma’s Nexcella announces NXC-201 clinical data
- Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank